Eikon Therapeutics, Inc. Common Stock (EIKN) vs ARS Pharmaceuticals, Inc. (SPRY)
A side-by-side comparison of Eikon Therapeutics, Inc. Common Stock and ARS Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EIKN
Eikon Therapeutics, Inc. Common Stock
$7.51HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SPRY
ARS Pharmaceuticals, Inc.
$4.30HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — EIKN vs SPRY
growth of $100 · dividends reinvested · last 1yEIKN -49.7% (-49.7%/yr)SPRY -57.7% (-57.7%/yr)EIKN compounded faster over this window
EIKN SPRY
EIKN vs SPRY: by the numbers
- •SPRY is the larger company ($427M vs $407M market cap).
- •Both run net losses; EIKN's is the smaller (0.00% vs -184.24% net margin).
Metrics side by side
Valuation
| Metric | EIKN | SPRY |
|---|---|---|
| P/S ratio | N/A | 3.65 |
| P/B ratio | 0.87 | 34.09 |
Profitability
| Metric | EIKN | SPRY |
|---|---|---|
| Gross margin | 0.00% | 73.89% |
| Operating margin | 0.00% | -212.92% |
| Net margin | 0.00% | -184.24% |
| ROE | -69.06% | -1721.80% |
| ROIC | -46.16% | -114.65% |
Growth (annualized)
| Metric | EIKN | SPRY |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 36.43% |
| Total return CAGR (5Y) | N/A | -16.35% |
Go deeper
Dig into the metrics
Eikon Therapeutics, Inc. Common Stock ROEARS Pharmaceuticals ROEEikon Therapeutics, Inc. Common Stock operating marginARS Pharmaceuticals operating marginEikon Therapeutics, Inc. Common Stock revenue growthARS Pharmaceuticals revenue growthEikon Therapeutics, Inc. Common Stock free cash flowARS Pharmaceuticals free cash flow
Eikon Therapeutics, Inc. Common Stock & ARS Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.